Eris Lifesciences Ltd. (ERIS): Eris Lifesciences 52 Week Low Streak: Second Straight Session Near One-Year Low

Eris Lifesciences 52 Week Low Streak has now stretched into a second straight session, and that sequence matters more than the one-day move. On both trading days in the streak, the stock stayed within 2% of its 52-week low, showing that the downside pressure did not fade after the first close near the yearly bottom. The cumulative move across the Eris Lifesciences 52 Week Low Streak is -2.91%, which frames the pattern as a continued decline rather than an isolated slip. The latest print of Rs 1,200 matched the lower end of the session and kept Eris Lifesciences Share Price pinned close to the same level that defined the earlier session. For market readers, the key point is that Eris Lifesciences 52 Week Low Streak is now a two-session decline story, not a one-off market dip.

The day’s session added to that picture. Eris Lifesciences opened at Rs 1,223.3, which was also the high of the day, then moved lower to Rs 1,200 and ended there. The stock finished below the previous close of Rs 1,218.45, marking a fall of Rs 18.45 or 1.51% for the session. Because the close sat at the low of the day’s range, the Eris Lifesciences 52 Week Low Streak was reinforced by the intraday path as well as the closing level. This is important for the Eris Lifesciences 52 Week Low Streak because it confirms that sellers controlled the session after the early high, and Eris Lifesciences Share Price did not recover above the opening level. The repeated close near the yearly floor also keeps the Eris Lifesciences 52 Week Low Streak in the market conversation for a second day running.

Looking at the full streak rather than a single close, the sequence shows two nearby lows rather than one sharp washout followed by a rebound. That matters because a repeated close near the same yearly floor can keep the Eris Lifesciences 52 Week Low Streak in focus even when the daily move appears modest. The latest price action also leaves the stock at a market capitalisation of Rs 17,148.09 crore, so the weakness is occurring in a large listed pharmaceutical company rather than in a small, illiquid name. In that context, Eris Lifesciences 52 Week Low Streak is not just a headline about a single print; it is a description of how the stock has behaved across two consecutive sessions. The latest Eris Lifesciences Share Price of Rs 1,200 sits exactly at the low end of the session, which keeps the focus on downside follow-through. The Eris Lifesciences 52 Week Low Streak therefore reflects repeated weakness, not a brief dip that quickly eased.

For readers comparing the two days in the Eris Lifesciences 52 Week Low Streak, the pattern is simple: both sessions stayed near the 52-week low, and both sessions failed to pull the stock meaningfully away from that area. The cumulative decline of 2.91% across the streak underlines that the weakness is building over more than one trading day. In a decline story, that repeated proximity to the low is the key signal, not any attempt to frame the move as strength or recovery. The Eris Lifesciences 52 Week Low Streak therefore reflects a sustained breakdown in the recent price path, while Eris Lifesciences Share Price remains under pressure at the bottom of the day’s range. The second straight session adds emphasis because the market did not reverse the prior day’s tone; it extended the same downward pattern.

The broader interpretation of the Eris Lifesciences 52 Week Low Streak is that the stock has spent back-to-back sessions close to the same yearly trough, which usually keeps attention on whether weakness is becoming persistent rather than temporary. In this case, the supplied figures show a clean two-session sequence, a negative cumulative change, and a close that finished at the low of the session. That combination gives the Eris Lifesciences 52 Week Low Streak more weight than a single headline drop. For those following Eris Lifesciences Share Price, the concern is simply that the price has remained pinned near the lower edge of the recent range while the streak continues. The data points together tell one factual story: the decline has persisted for two consecutive sessions.

Eris Lifesciences Ltd. (ERIS) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 17,148.09 crore
P/E Ratio	26.25x
P/B Ratio	4.19x
ROE	19.23%
ROCE	14.47%
EPS	Rs 46.41
Book Value Per Share	Rs 290.65
Dividend Yield	0%

Eris Lifesciences Ltd. (ERIS) fundamental metrics show P/E 26.25x, P/B 4.19x, ROE 19.23%, ROCE 14.47%. These figures provide context only and are not a buy or sell signal.

Eris Lifesciences Ltd. has a market capitalisation of Rs 17148.09 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 26.25x, P/B at 4.19x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 19.23% and ROCE of 14.47%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 46.41, book value per share of Rs 290.65, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 28.59x, median ROE of 11.7%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	26.25x
Benchmark Median P/E	28.59x
Benchmark Average P/E	42.09x
Benchmark P/E Range	0x to 699.02x
Company P/B Ratio	4.19x
Benchmark Median P/B	2.87x
Company ROE	19.23%
Benchmark Median ROE	11.7%
Company ROCE	14.47%
Benchmark Median ROCE	13.46%
Company Market Capitalisation	Rs 17,148.09 crore
Benchmark Median Market Cap	Rs 773.14 crore

Eris Lifesciences Ltd. (ERIS) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Eris Lifesciences Ltd. (ERIS) has a P/E ratio of 26.25x, which is below the benchmark median of 28.59x, a difference of -8.18%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Eris Lifesciences Ltd. (ERIS) has a ROE of 19.23%, which is above the benchmark median of 11.7%, a difference of +64.36%. Eris Lifesciences Ltd. (ERIS) has a ROCE of 14.47%, which is above the benchmark median of 13.46%, a difference of +7.5%.

Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Suven Pharmaceuticals Ltd.	COHANCE	17,366.09	164.5	4.54	4.02	6.12
Jubilant Pharmova Ltd.	JUBLPHARMA	16,840.79	47.49	2.34	5.97	8.69
Alembic Pharmaceuticals Ltd.	APLLTD	16,790.42	24.38	2.89	12.35	11.74
Glenmark Life Sciences Ltd.	ALIVUS	16,695.69	27.69	4.79	18.41	24.61
ONESOURCE SPECL PHARMA L	ONESOURCE	17,963.65	0	3.11	-1.26	0.44

Eris Lifesciences Ltd. (ERIS) has a P/E ratio of 26.25x compared with the displayed peer median of 27.69x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 19.23% compares with a peer median of 5.97% across the companies shown in the table. ROCE stood at 14.47% versus the displayed peer median of 8.69%, providing a capital-efficiency comparison. Eris Lifesciences Ltd. (ERIS) has a market capitalisation of Rs 17,148.09 crore. Among the 5 peers shown, 2 have a larger market capitalisation.

About Eris Lifesciences Ltd. (ERIS)

Eris Lifesciences Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company’s listed profile, market capitalisation and financial ratios make it an established mid-to-large name in the Indian market. Within this framework, the Eris Lifesciences 52 Week Low Streak is a market event tied to price behavior, not a statement about the business model itself. The current Eris Lifesciences Share Price remains close to the low of the recent range, and that keeps the stock on yearly-low watch for traders and market followers. The same factual setup also explains why the Eris Lifesciences 52 Week Low Streak continues to appear in stock news and market screens focused on downside follow-through. The second straight session is the main takeaway, because it confirms that the decline did not stop after the prior close near the yearly low.

As always, this update is a factual record of the session, the streak and the supplied fundamentals. It does not turn the Eris Lifesciences 52 Week Low Streak into a recommendation or a forecast. The main takeaway is simply that the stock has remained near its 52-week low for a second straight session, with a cumulative decline of 2.91% across the streak and a close at Rs 1,200. That makes the Eris Lifesciences 52 Week Low Streak a clear downside story for the day, while Eris Lifesciences Share Price stays under pressure at the lower edge of its recent trading band. For readers tracking the stock over multiple sessions, the repeated lows are the point: the price stayed close to the same floor on both days, and the streak now has clear two-session continuity.

Eris Lifesciences Ltd. (ERIS) 52 Week Low Streak: Consecutive Low Analysis

Metric	Value
Current Price	Rs 1,200
Previous Close	Rs 1,218.45
Today's Move	Rs -18.45 (-1.51%)
Open	Rs 1,223.3
High	Rs 1,223.3
Low	Rs 1,200
Market Capitalisation	Rs 17,148.09 crore

Eris Lifesciences Ltd. (ERIS) traded at Rs 1,200 versus the previous close of Rs 1,218.45, a fall of 1.51%. The stock opened at Rs 1,223.3, reached a high of Rs 1,223.3, touched a low of Rs 1,200.

Track Eris Lifesciences Ltd. (ERIS) Share Price on Univest

Use Eris Lifesciences Ltd. (ERIS) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.